Washington Drug Letter
Eli Lilly, Pfizer and Bristol-Myers Squibb (BMS) have joined AstraZeneca as targets of subpoenas from the California Office of the Attorney General over marketing practices for top-selling antipsychotic drugs.
The Eli Lilly subpoena is for documents relating to its marketing and promotional practices for Zyprexa (olanzapine), which is used to treat schizophrenia and bipolar disorder, as well as the company’s efforts to obtain and maintain the drug’s status on California’s formulary and its remuneration of healthcare providers.
Company spokesman Phil Belt told WDL the company is cooperating with the request and is not adding anything else to its announcement.
The company also said that it continues to be a defendant in many Zyprexa product liability lawsuits, the majority of which allege that the drug caused or contributed to diabetes or high blood-glucose levels. Almost all of the federal lawsuits are part of a “multi-district litigation” before Judge Jack Weinstein in the Federal District Court for the Eastern District of New York…